# Project Completion Summary

**Project:** DUR Risk Map — Interactive ingredient-level contraindication network explorer  
**Date:** 2026-03-25  
**Status:** ✅ Complete (MVP + Analysis)

---

## Deliverables

### 1. **Core Application**
- `app.py` — Streamlit prototype with ego-network visualization
- Live deployment: https://dur-network-visualization-uwk4hnvx6ejtpdatrthux7.streamlit.app
- Features: drug selector, interactive graph, overlay metadata, neighbor tables, hub summary

### 2. **Analysis Notebook**
- `notebooks/02_analysis_findings.ipynb` — 6 key findings from the contraindication network
- Includes: data exploration, charts, centrality analysis, vulnerability flag analysis, community detection, cross-file insights

### 3. **Processed Data**
- `data/processed/ac_edge_table_english.csv` — 844 canonicalized contraindication pairs
- `data/processed/ac_node_table_with_overlay.csv` — 386 ingredients with BC/CC/DC/FC/GC overlays

### 4. **Documentation**
- `README.md` — Project overview, features, method, findings table
- `docs/00_project_brief.md` — One-sentence goal and scope
- `docs/01_data_understanding.md` — Raw file exploration notes
- `docs/02_data_dictionary.md` — Column descriptions and meanings
- `docs/03_design_decisions.md` — Key modeling choices
- `docs/04_todo.md` — Task tracking
- `docs/05_dev_log.md` — Development history
- `docs/06_project_complete.md` — This file

---

## Key Findings Summary

| Finding | Insight | Clinical Importance |
|---------|---------|-------------------|
| **F1** | Contrast + Metformin pairs dominate raw_count | Formulation count inflates evidence, but mechanism is well-documented |
| **F2** | Tizanidine, Fluvoxamine are network bridges | Removing them fragments the network — structural bottlenecks |
| **F3** | 11 drugs flagged for all 3 vulnerable populations | Antipsychotics + NSAIDs represent broadest prescribing constraints |
| **F4** | 31 communities mirror pharmacological mechanisms | Network structure is mechanistically sound and coherent |
| **F5** | 38 double-hit pairs (GC + AC simultaneous) | Strongest regulatory signals: NSAID/triptan pairs most notable |
| **F6** | 6 top-20 hubs also DC dose-caution flagged | Ketorolac is most multiply-constrained drug in dataset |

---

## Architecture

```
dur-network-visualization/
├── app.py                          # Streamlit MVP
├── README.md                       # Project overview + findings table
├── requirements.txt                # Python dependencies
├── data/
│   ├── raw/                        # 7 original Korean DUR CSV files
│   └── processed/
│       ├── ac_edge_table_english.csv
│       └── ac_node_table_with_overlay.csv
├── docs/
│   ├── 00_project_brief.md
│   ├── 01_data_understanding.md
│   ├── 02_data_dictionary.md
│   ├── 03_design_decisions.md
│   ├── 04_todo.md (completed)
│   ├── 05_dev_log.md
│   └── 06_project_complete.md (this file)
├── notebooks/
│   ├── 01_ac_explore.ipynb         # Initial exploration
│   └── 02_analysis_findings.ipynb  # Final 6 findings + charts
└── src/
    ├── gc_analysis.py              # GC/AC cross-analysis
    ├── update_summary.py           # Notebook table updates
    └── fix_findings.py             # Logic corrections
```

---

## How to Run Locally

```bash
# Clone and navigate
git clone https://github.com/goneyak/dur-network-visualization.git
cd dur-network-visualization

# Create virtual environment
python3 -m venv .venv
source .venv/bin/activate

# Install dependencies
pip install -r requirements.txt

# Run Streamlit app
streamlit run app.py
```

Then visit `http://localhost:8501` in your browser.

---

## Tech Stack

- **Data Processing:** pandas, numpy
- **Graph:** NetworkX (graph construction, centrality measures, community detection)
- **Visualization:** Plotly (interactive charts), NetworkX (ego-network layout)
- **App Framework:** Streamlit
- **Analysis:** scipy, matplotlib (community detection, Venn diagrams)
- **Deployment:** Streamlit Cloud

---

## What Worked Well

✅ **Modular data pipeline:** Raw CSV → canonical edges → node overlays → graph → app  
✅ **Ego-network interface:** Single-drug focus reduces cognitive load  
✅ **Metadata overlays:** BC/CC/DC/FC flags add clinical context without bloating UI  
✅ **Cross-file analysis:** GC + AC cross-check revealed 38 double-hit pairs (F5)  
✅ **Community detection:** Louvain algorithm produced pharmacologically meaningful clusters  
✅ **Documentation:** Clear design decisions + dev log enabled rapid iteration

---

## Limitations & Future Work

### Current Limitations
- Ego-network only; no full-network path analysis
- Degree ≠ absolute clinical risk (network topology artifact)
- EC (duration caution) and IC (excipient caution) files not yet integrated
- No patient-level decision support

### Possible Extensions
1. **Degree 2+ neighborhoods:** Show contraindication paths beyond immediate neighbors
2. **GC/DC app features:** Add therapeutic group filtering and dose caution highlights
3. **EC/IC integration:** Expand to all 7 DUR file types
4. **Clinical validation:** Survey pharmacists to validate network findings
5. **Publication:** Prepare network analysis for academic journal submission

---

## Conclusion

DUR Risk Map successfully transforms Korean public DUR ingredient data into an interactive, network-based exploration tool. The 6 findings from the analysis provide actionable insights into contraindication patterns, hub drugs, vulnerable-population risks, and multiply-constrained compounds. The project is production-ready as a **public health informatics resource** for pharmacists, clinicians, and drug safety researchers.

**Next steps:** This MVP is suitable for deployment, community feedback collection, or integration into existing clinical systems. Extended versions could support patient-level decision support or pharmaceutical curriculum development.
